Taconic To Promote And Sell Medicyte Hepatocyte Products

Taconic and Medicyte inked a marketing and sales agreement through which Taconic will promote and sell human primary upcyte® hepatocyte cell strains and corresponding media developed by Medicyte for in vitro applications. The firms say the agreement strengthens Taconic's tADMET™ portfolio of models and provides Medicyte broader distribution of its products as well as increased market visibility and entrance into new markets for its hepatocyte cell strains.

The Taconic tADMET portfolio is a collection of genetically and tissue humanized mouse models, as well as in vitro tools and services that aim to improve the predictability of drug responses in humans. Taconic says that Medicyte's products and services will enhance its tADMET portfolio and that it will provide access to that portfolio through its combined marketing of predictive in vivo models and upcyte hepatocytes.

"The combination of the Medicyte and Taconic portfolios represents a perfect match to offer researchers a complete package for in vitro and in vivo studies," said Joris Braspenning, Ph.D., managing director of Medicyte, in a statement.

This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.